CIK 0001453687
- Non-accelerated filer
- Smaller reporting company
Cartesian Therapeutics, Inc.
Sign in to watch- Ticker
- RNAC
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 301-348-8698
- Business address
- 7495 NEW HORIZON WAY, FREDERICK, MD, 21703
- Former names
- SELECTA BIOSCIENCES INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2022-01-03 | Myers Scott Dunseth Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-01-03 | Kishimoto Takashi Kei Chief Scientific Officer | Grant or award | +72,000 | 271,769 | ||
| 2022-01-03 | Kishimoto Takashi Kei Chief Scientific Officer | Grant or award · Employee Stock Option (right to buy) | +340,000 | 340,000 | ||
| 2022-01-03 | Johnston Lloyd P. Chief Operations Officer | Grant or award | +72,000 | 178,715 | ||
| 2022-01-03 | Johnston Lloyd P. Chief Operations Officer | Grant or award · Employee Stock Option (right to buy) | +340,000 | 340,000 | ||
| 2022-01-03 | DeSilva Nishan M Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-01-03 | COX CARRIE SMITH Director | Grant or award · Stock Option (Right to Buy) | +60,000 | 60,000 | ||
| 2022-01-03 | Brunn Carsten President and CEO | Grant or award | +226,300 | 531,555 | ||
| 2022-01-03 | Brunn Carsten President and CEO | Grant or award · Employee Stock Option (right to buy) | +1,056,100 | 1,056,100 | ||
| 2022-01-03 | BARABE TIMOTHY C Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2022-01-03 | ANDO GORAN Director | Grant or award · Stock Option (Right to Buy) | +40,000 | 40,000 | ||
| 2021-12-15 | SPRINGER TIMOTHY A Director | Purchase | +211,190 | $2.99 | $631K | 23,186,890 |
| 2021-12-13 | SPRINGER TIMOTHY A Director | Purchase | +14,592 | $2.98 | $43K | 22,975,700 |
| 2021-12-10 | TRABER PETER G Chief Medical Officer | Sale | −4,083 | $2.99 | $12K | 164,381 |
| 2021-12-10 | Kishimoto Takashi Kei Chief Scientific Officer | Sale | −4,370 | $2.99 | $13K | 199,769 |
| 2021-12-10 | Johnston Lloyd P. Chief Operations Officer | Sale | −4,370 | $2.99 | $13K | 106,715 |
| 2021-12-10 | Brunn Carsten President and CEO | Sale | −17,196 | $2.99 | $51K | 305,255 |
| 2021-12-10 | SPRINGER TIMOTHY A Director | Purchase | +58,681 | $2.99 | $175K | 22,961,108 |
| 2021-12-09 | SPRINGER TIMOTHY A Director | Purchase | +3,748,000 | $3.06 | $11.5M | 22,902,427 |
| 2021-12-08 | TRABER PETER G Chief Medical Officer | Grant or award | +13,750 | 168,464 |
Page 22 of 25 · 495 trades